

Associations of inflammatory biomarkers with cardiovascular burden and predicted risk in people with HIV

Luxsena Sukumaran¹, Jasmini Alagaratnam², Alejandro Abner Garcia Leon³, Frank A Post⁴, Memory Sachikonye⁵, Jaime Vera⁶, Patrick WG Mallon⁷, Maxine Ng⁸, Alejandro Andreas-Pinto¹, Jane Anderson⁹, Fiona Burns¹, Caroline A Sabin¹, Alan Winston⁸

¹Institute for Global Health, UCL, London, United Kingdom; ²Chelsea & Westminster Hospital NHS Foundation Trust, London, UK; ³Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland; ⁴King's College London, London, United Kingdom; ⁵UK Community Advisory Board (UK-CAB), United Kingdom; ⁶Brighton and Sussex Medical School, Brighton and Hove, United Kingdom; ⁷HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland; ⁸Imperial College London, London, United Kingdom; ⁹Homerton University Hospital NHS Trust, United Kingdom

BACKGROUND

People with HIV have an elevated risk of cardiovascular disease (CVD), driven in part by persistent systemic inflammation [1]. Specific inflammatory biomarkers, including IL-6, IL-10, TNF- α , CCL2/MCP-1, and CXCL1, have been implicated in CVD pathogenesis [2]. We examined associations between these biomarkers, current CVD burden and predicted 10-year CVD risk in adults with HIV enrolled in the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study to better understand inflammation-related cardiovascular risk.

METHODS

STUDY POPULATION

The POPPY study collects data on sociodemographic, lifestyle and clinical characteristics from three groups: 699 people with HIV aged ≥ 50 years, 374 people with HIV aged < 50 years, and 304 people without HIV aged ≥ 50 years [3].

CVD BURDEN Z-SCORES

A cardiovascular disease (CVD) pattern was identified in participants with HIV using principal component analysis (PCA) at baseline (April 2013-January 2016).

Comorbidities (PCA loading) correlated with this pattern included coronary artery bypass grafting/percutaneous transluminal coronary angioplasty (0.68), heart failure (0.62), hypertension (0.70), ischaemic heart disease (0.72), myocardial infarction (0.69), peripheral vascular disease (0.46), renal problems (0.40) and dyslipidemia (0.34).

Participant burden z-scores were calculated using PCA loadings and information on the presence/absence of these comorbidities, and standardised (baseline mean and standard deviation). CVD burden z-scores > 0 indicated higher CVD burden relative to the cohort mean.

INFLAMMATORY BIOMARKERS

Five biomarkers previously linked to CVD (IL-6, IL-10, TNF- α , CCL2/MCP-1, CXCL1) were measured using the OLINK platform and reported as normalised protein expression (NPX; log₂ scale).

PREDICTED CVD RISK

Ten-year CVD risk was estimated in POPPY participants with HIV aged ≥ 40 years without prior myocardial infarction or stroke using SCORE2.

STATISTICAL ANALYSIS

Linear regression assessed associations between biomarker NPX values and both baseline CVD burden z-scores and SCORE2.

Models adjusted for age, sex, ethnicity, body mass index (BMI), smoking, nadir CD4+, years since HIV diagnosis and prior AIDS event.

IL-6 and IL-10 were differentially associated with PCA-derived CVD burden and 10-year CVD risk, with stronger links to predicted risk, highlighting their potential value to identify individuals at elevated cardiovascular risk.


RESULTS

- Analyses included 682 adults with HIV (median [IQR] age 53 [49-60] years; 87% male; 88% White) (Table 1).
- At baseline, the median [IQR] CVD burden z-score and SCORE2 were -0.62 (-0.62, 0.56) and 4.07 (2.45, 5.84), respectively.
- Median [IQR] biomarker NPX values: IL-6 -0.01 [-0.47, 0.62]; IL-10 0.00 [-0.35, 0.50]; TNF- α 0.00 [-0.28, 0.36]; CCL2/MCP-1 0.01 [-0.29, 0.34]; CXCL1 0.07 [-0.77, 0.73].
- After adjustment, higher IL-6 was associated with greater CVD burden ($\beta = 0.07$ [0.01, 0.14]) and SCORE2 ($\beta = 0.68$ [0.42, 0.94]). IL-10 was inversely associated with SCORE2 ($\beta = -0.37$ [-0.60, -0.13]).
- CCL2/MCP-1 and CXCL1 showed no clear associations with CVD outcomes after adjustment.

Table 1. Baseline characteristics of study participants

Characteristic	Total (n=682)
n (%) or median (IQR)	
Age (years)	53 (49 - 60)
Gender	
Male	594 (87.1)
Female	88 (12.9)
Ethnicity	
Black-African	83 (12.2)
White	599 (87.8)
BMI (kg/m ²)	25.6 (23.3 - 28.1)
Smoking status	
Never	272 (39.9)
Past	242 (35.5)
Current	168 (24.6)
Alcohol use	
Never	50 (7.3)
Past	81 (11.9)
Current	551 (80.8)
CVD burden z-score	-0.62 (-0.62 - 0.56)
Predicted 10-year risk (SCORE2)	4.07 (2.45 - 5.84)
HIV-specific clinical factors	
Years since HIV diagnosis	14.5 (8.8 - 20.8)
On ART	673 (98.7)
Current CD4+ count (cells/ml)	631 (477 - 810)
Nadir CD4+ count (cells/ml)	197 (100 - 289)
Prior AIDS event	209 (30.7)

Figure 1. Associations of log-transformed normalised biomarker values with CVD burden z-scores and 10-year SCORE2 risk scores among POPPY participants with HIV (n=682). Crude and adjusted beta estimates with 95% confidence intervals are shown.



The CVD burden models were adjusted for age, sex, ethnicity, BMI, smoking status, nadir CD4+, years since HIV diagnosis, and prior AIDS event. CVD risk models were adjusted for all covariates except age, sex and smoking status, which are already incorporated in the risk score calculation.

CONCLUSIONS

- PCA-derived **CVD burden z-scores provided a nuanced measure of CVD morbidity**, capturing correlated cardiovascular events beyond simple counts.
- Inflammatory biomarkers showed differential associations, with **stronger associations observed for predicted 10-year CVD risk than current CVD burden**, partly reflecting age, smoking and other lifestyle factors.
- Higher **IL-6 was linked to both baseline CVD burden and predicted 10-year risk**; IL-10 was inversely associated with predicted risk.
- Future studies should explore IL-6 and IL-10 levels over time** to improve CVD prediction and test whether targeting these pathways can reduce cardiovascular morbidity in people with HIV.

REFERENCES

- Ntsekhe M, et al. Circulation 2023;147(1):83-100
- Liu Y, et al. Front Cardiovasc Med 2023;10:1175174
- Bagkeris E, et al. Int J Epidemiol 2018;47:1391-1392e

ACKNOWLEDGEMENTS

POPPY Management Team: Saumitro Deb, Nicki Doyle, Paddy Mallon, Maxine Ng, Claire Petersen, Frank Post, Caroline Sabin, Memory Sachikonye, Alan Winston **POPPY Study Steering Committee:** Jasmini Alagaratnam, Jane Anderson, David Asboe, Marta Boffito, Fiona Burns, Aoife Cotter, Saumitro Deb, Nicki Doyle, Eoin Feeney, Paddy Mallon, Carlos Mejia, Maxine Ng, Claire Petersen, Frank Post, Caroline Sabin, Memory Sachikonye, Jaime Vera, Laura Waters, Alan Winston **POPPY Sites:** St Stephen's Centre, Chelsea and Westminster Hospital (Marta Boffito, Jasmini Alagaratnam, Ruth Byrne, Alexia Cheneau, Rosa Diaz Echeverria, Serge Fedele, Mohammed Hassan, Darwin Matila, Roya Movahedi, Beatrice Ouma, Javier Pinedo, Kathleen Ridor, Jad Salha, Sharom Scarpetta, Reda Yassein) Homerton Sexual Health Services, Homerton University Hospital (Jane Anderson, Tracey Fong, Lidia Ignatov, Jagrul Miah, Iain Reeves), Caldecot Centre, King's College Hospital (Frank Post, Birgit Barbini, Lucy Campbell, Luella Hanbury, Rachel Hung, Leigh McQueen, Zoe Ottaway, Daniel Trotman, Emily Wandolo) Mortimer Market Centre, Central and Northwest London NHS Foundation Trust (Laura Waters, Fowsiya Nur, Brittney Prusty, Sandra Coombes, Gosala, Gopalakrishnan, Ebuloluwa Taiwo, Christos Karathanasis, Laura Hennelly, Claudia Benatar, Alejandro Arenas Pinto) Ian Charleson Day Centre, Royal Free Hospital (Fiona Burns, Tom Allan, Jonathan Edwards, Tom Fernandez, Jia Bo He, Katie Spears, Abigail Tobin) Clinical Research Facility, Royal Sussex County Hospital (Jaime Vera, Tanya Adams, Lisa Barbour, Kay Franklin, Chioma Iwuchukwu, Donards Tanedo, Andrea Terlingo, Vittorio Trevis, Mikaela Vinick) Clinical Trials Centre, St. Mary's Hospital London (Alan Winston, Wilbert Ayap, Merle Henderson, Ishrat Jahan, Ian McGuinness, Idah Mojela, Marcelino Molina, Jacquie Ujetz) Catherine McAuley Centre, Mater Misericordiae University Hospital (Carlos Mejia Nijat Ahmadi, Alejandro Garcia, Binsa Jose) St Vincent's University Hospital (Eoin Feeney, Alejandro Garcia, Fiorina Rigonat, Stefano Savinelli) **POPPY methodology/statistics:** Caroline Sabin, Saumitro Deb, Hajra Okhai, Luxsena Sukumaran **Funders:** We acknowledge the use of the National Institute for Health Research (NIHR)/Wellcome Trust Clinical Research Facility at King's College Hospital. The research is also funded by the National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. Supported in part by research grants from Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC, Viiv Healthcare and Gilead Sciences.

PLAIN LANGUAGE SUMMARY

People with HIV have a higher risk of heart disease, partly due to ongoing inflammation. This study found that several inflammation-related proteins, including TNF- α , IL-6, IL-10, were linked differently to existing heart problems or risk factors versus future cardiovascular risk, suggesting these proteins could help predict individuals who may develop heart-related conditions over the next 10 years.